Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant
Immunome, Inc. (IMNM)
Company Research
Source: Business Wire
- Data show that combination of two antibodies in Immunome’s cocktail successfully neutralized the Omicron variant in vivo in hamsters -- IMM20253 antibody also retained activity against BA.2 subvariant in pseudovirus testing in vitro, with additional testing underway - EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that it published data demonstrating that its COVID-19 antibody cocktail, IMM-BCP-01, potently cleared the Omicron variant (BA.1) of SARS-CoV-2 when tested in vivo in hamsters. Additional in vitro testing of a SARS-CoV-2 pseudovirus also showed that IMM20253, one of the antibodies in Immunome’s cocktail, successfully neutralized the Omicron subvariant (BA.2).When tested in hamster models, IMM-BCP-01 retained full coverage against the Omicron variant. Specifically, the data suggest strong activity of two ant
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome, Inc. (NASDAQ: IMNM) is now covered by analysts at Guggenheim. They set a "buy" rating and a $35.00 price target on the stock.MarketBeat
- Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling [Seeking Alpha]Seeking Alpha
- Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual MeetingBusiness Wire
- Immunome, Inc. (NASDAQ: IMNM) had its price target raised by analysts at Wedbush from $27.00 to $33.00. They now have an "outperform" rating on the stock.MarketBeat
IMNM
Sec Filings
- 4/3/24 - Form S-3ASR
- 4/3/24 - Form S-3ASR
- 3/28/24 - Form 10-K
- IMNM's page on the SEC website